Vericel Corporation (NASDAQ:VCEL) Files An 8-K Other Events

Item 8.01 Other Events.

On December14, 2016, the Company issued a press release entitled
FDA Approves MACI for the Treatment of Symptomatic Cartilage
Defects of the Knee in Adults. A copy of the press release is
attached hereto as Exhibit99.1 and is incorporated herein by
reference.

Item 9.01 Exhibits.

(d) Exhibits.

About Vericel Corporation (NASDAQ:VCEL)

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Vericel Corporation (NASDAQ:VCEL) Recent Trading Information

Vericel Corporation (NASDAQ:VCEL) closed its last trading session up +1.40 at 4.00 with 2,013,708 shares trading hands.